Current and emerging pharmacological therapy for non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease

Published:2017-11-14 Issue:42 Volume:23 Page:7495-7504
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:
Short-container-title:WJG

Author:

Eshraghian Ahad

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference103 articles.

1. Eshraghian A, Dabbaghmanesh MH, Eshraghian H, Fattahi MR, Omrani GR. Nonalcoholic fatty liver disease in a cluster of Iranian population: thyroid status and metabolic risk factors. Arch Iran Med 2013; 16: 584-589

2. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease

3. NAFLD, NASH and liver cancer

4. Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

5. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protective effects of syringic acid in nonalcoholic fatty liver in rats through regulation of Nrf2/HO‐1 signaling pathway;Journal of Biochemical and Molecular Toxicology;2024-08-15

2. Bile acids and coronavirus disease 2019;Acta Pharmaceutica Sinica B;2024-05

3. Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-02

4. NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials;Frontiers in Medicine;2023-08-01

5. Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta‐analysis on randomized controlled trials;Journal of Digestive Diseases;2023-06